Quantcast

Industry news that matters to you.  Learn more

GeneNews’ First U.S. Marketing Partner Launches ColonSentry

GeneNews Limited (TSX: GEN), a company focused on developing and commercializing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that Enzo Clinical Labs, a division of Enzo Biochem, Inc. (NYSE:ENZ), has launched ColonSentry®, the world’s first blood test to assess an individual’s current risk for colorectal cancer.

GeneNews’ US Partner Obtains Approval to Market ColonSentry

GeneNews Limited (TSX: GEN), a company focused on developing and commercializing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that Enzo Clinical Labs, a division of Enzo Biochem, Inc. (NYSE:ENZ), has received approval from New York State’s Department of Health to market ColonSentry, a blood-based test to assess an individual’s current risk for colorectal cancer. Enzo has exclusive rights to market the ColonSentry test in the states of New York and New Jersey.

GeneNews Enters Into MOU With Shanghai Biochip to Establish First Sentinel Centre for Personalized Medicine

GeneNews Limited, a molecular diagnostics company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has signed a memorandum of understanding (“MOU”) with Shanghai Biochip Co. Ltd. (“SBC”), a leading Chinese engineering centre for advanced microarray and gene expression profiling technologies, to enter into a strategic alliance to establish the first Sentinel Centre for Personalized Medicine in China.

GeneNews’ Sentinel Principle Used to Discover New Blood Based Biomarkers for Nasopharyngeal Carcinoma

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that a presentation entitled “Nasopharyngeal Carcinoma Biomarkers derived using Peripheral Blood Transcriptome” was given today at the 2011 Asia Pacific Cancer Conference, Kuala Lumpur, Malaysia.

GeneNews Announces SentinelGx Pharmacogenomic and Companion Diagnostic BloodRNA Service

GeneNews Limited, a molecular diagnostics company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the launch of SentinelGx, a suite of pharmacogenomic and companion diagnostic BloodRNA services for drug development and personalized health management applications (“SentinelGx”). The SentinelGx services provide complete whole blood transcriptome analysis for RNA expression profiling of inflammatory pathways, immune system response and cell signaling based on the Company’s patented Sentinel Principle technology. A catalog of over 2,200 TaqMan BloodRNA Profiles is now available including pathway-specific, disease-specific and drug-specific gene signature panels clinically proven to express in whole blood. The disease-specific panels include gene signatures for numerous types of cancer, autoimmune, cardiovascular, infectious and neurological diseases. In connection with the SentinelGx launch, GeneNews also announced the appointment of Karl Wassmann to the newly created position of Executive Vice President, US Corporate Development to manage the SentinelGx services.